Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
INCIVO® (telaprevir) Receives European Commission Approval for Twice Daily Dosing for Treatment of Genotype-1 Chronic Hepatitis C Virus (HCV)

Janssen Infectious Diseases-Diagnostics announced today that the European Commission has approved a new twice-daily dosing of INCIVO® (telaprevir), a direct-acting antiviral hepatitis C protease inhibitor, in combination with pegylated-interferon and ribavirin (PR) for naive and previous-treatment experienced patients.

Published
31 May 2013
From
PR Newswire
Hepatitis C treatment gap in Europe: France doing well but Italy treated fewer than one in a hundred patients in 2010

France led the world in the proportion of its hepatitis C patients who received treatment in 2010, but some countries in southern and eastern Europe had treatment

Published
28 May 2013
By
Keith Alcorn
Recent Advances in the Treatment of Chronic Hepatitis C Threaten to Leave Some Parts of the World Behind

A scenario may develop where hepatitis C is largely eradicated from the developing world but exits in large pockets in developing countries.

Published
21 May 2013
From
Medscape (requires registration)
Triple therapy for hepatitis C is effective after liver transplantation, but side-effects are common

Adding the approved HCV protease inhibitor telaprevir (Incivo or Incivek) to pegylated interferon and ribavirin can increase sustained viral response rates even for difficult-to-treat liver transplant recipients, but

Published
16 May 2013
By
Liz Highleyman
Movement for global access to hepatitis C treatment building momentum

Access to hepatitis C treatment in low- and middle-income countries is being restricted by the high cost of interferon and a lack of commitment to treating the

Published
09 May 2013
By
Keith Alcorn
Report highlights major failings in UK response to hepatitis C

The UK needs to “be doing so much more” in response to hepatitis C, according to a new report. Supported by a consortium of leading hepatitis C

Published
07 May 2013
By
Michael Carter
Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets

A new analysis from Frost & Sullivan, "Analysis of European Hepatitis B and C Therapeutics Markets" finds that the Hepatitis B market earned revenues of $1.26 billion in 2012 and estimates this to reach $1.89 billion in 2019, while the Hepatitis C market is projected to expand from $2.40 billion to $3.66 billion over the same time period.

Published
01 May 2013
From
PR Newswire
Triple-drug HCV therapy comes with high risk of serious adverse events for people with cirrhosis

Currently available triple therapies for hepatitis C carry a high risk of serious side-effects for people in the most urgent need of treatment, and these patients have

Published
30 April 2013
By
Keith Alcorn
Hepatitis C Viral Load Fluctuates Without Treatment

Fluctuations in circulating hepatitis C virus RNA could be "clinically meaningful" in a substantial number of patients with chronic infection, and could influence the best time to prescribe antiviral therapy.

Published
05 April 2013
From
Medscape (requires registration)
Integrated Psych Care for High-Risk Hep C Patients May Increase Antiviral Treatment

Hepatitis C patients who have psychiatric disorders and problems with substance abuse may benefit from integrated care, a new study has found. More patients in integrated care began antiviral treatment and achieved a sustained viral response in a trial of 365 patients at three Veterans Affairs medical centers.

Published
27 March 2013
From
Medscape (requires registration)
← First12345...24Next →

Filter by country